Liu Ying L, Mathews Cara A, Simpkins Fiona, Cadoo Karen A, Provencher Diane, McCormick Colleen C, ElNaggar Adam C, Altman Alon D, Gilbert Lucy, Black Destin, Kabil Nashwa, Taylor Rosie N, Barnicle Alan, Munley Jiefen Y, Aghajanian Carol
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Weill Cornell Medical College, New York, New York, USA.
Cancer. 2025 Jan 15;131(2):e35707. doi: 10.1002/cncr.35707.
LIGHT (oLaparib In HRD-Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: germline BRCAm (gBRCAm), somatic BRCAm (sBRCAm), HRD-positive non-BRCAm, and HRD-negative. At the primary analysis, olaparib treatment demonstrated activity across all cohorts, with greatest efficacy in terms of objective response rate and progression-free survival observed in the g/sBRCAm cohorts. The authors report final overall survival (OS).
In this phase 2, open-label, noncomparative study, patients with PSROC and one or more prior line of platinum-based chemotherapy were assigned to cohorts by BRCAm and HRD status. OS was a secondary end point. Tumors were analyzed using Myriad BRACAnalysis CDx and MyChoice CDx assays; HRD-positive tumors were defined using a genomic instability score of ≥42.
Of 272 enrolled patients, 271 received olaparib and 270 met the inclusion criteria for the efficacy analysis. At data cutoff, 18-month OS rates in the gBRCAm, sBRCAm, HRD-positive non-BRCAm, and HRD-negative cohorts were 86.4%, 88.0%, 78.6%, and 59.6%, respectively. No new safety signals were observed. In a post hoc analysis, patients on treatment for >18 months were most frequently present in g/sBRCAm cohorts (31.0%).
Olaparib treatment continued to demonstrate benefit across all cohorts. Consistent with the primary analysis, the highest OS rates were observed in the BRCAm cohorts, regardless of g/sBRCAm. In patients without a BRCAm, a higher OS rate was observed in the HRD-positive non-BRCAm than the HRD-negative cohorts. These results highlight the importance of biomarker testing in this treatment setting.
LIGHT(奥拉帕利在HRD分组肿瘤类型中的应用;NCT02983799)前瞻性评估了奥拉帕利在铂敏感复发性卵巢癌(PSROC)患者中的治疗效果,这些患者根据已知的BRCA突变(BRCAm)和同源重组缺陷(HRD)状态被分配到不同队列:胚系BRCAm(gBRCAm)、体细胞BRCAm(sBRCAm)、HRD阳性非BRCAm和HRD阴性。在初步分析中,奥拉帕利治疗在所有队列中均显示出活性,在g/sBRCAm队列中观察到的客观缓解率和无进展生存期方面疗效最佳。作者报告了最终总生存期(OS)。
在这项2期、开放标签、非对照研究中,PSROC患者和接受过一种或多种铂类化疗方案的患者根据BRCAm和HRD状态被分配到不同队列。OS是次要终点。使用Myriad BRACAnalysis CDx和MyChoice CDx检测对肿瘤进行分析;HRD阳性肿瘤定义为基因组不稳定评分≥42。
在272例入组患者中,271例接受了奥拉帕利治疗,270例符合疗效分析的纳入标准。在数据截止时,gBRCAm、sBRCAm、HRD阳性非BRCAm和HRD阴性队列的18个月OS率分别为86.4%、88.0%、78.6%和59.6%。未观察到新的安全信号。在事后分析中,治疗时间>18个月的患者最常见于g/sBRCAm队列(31.0%)。
奥拉帕利治疗在所有队列中继续显示出益处。与初步分析一致,无论g/sBRCAm如何,BRCAm队列中的OS率最高。在没有BRCAm的患者中,HRD阳性非BRCAm队列的OS率高于HRD阴性队列。这些结果突出了生物标志物检测在这种治疗环境中的重要性。